Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 August 2022 | Story Leonie Bolleurs | Photo Francois van Vuuren, iFlair Photography
UFS Sasol Solar car
Team UFS, which has entered its solar-powered vehicle, Lengau (meaning Cheetah in Sesotho), will compete against more than 11 other teams, both local and international. Pictured here is the entire team during one of the road tests at Brandkop in Bloemfontein.

It is almost three years after Team UFS first decided to put a solar-powered vehicle on the road. Within a few days, this dream of participating in the international Sasol Solar Challenge will become a reality when they depart from Carnival City in Johannesburg on 9 September 2022.

For the challenge, the team of ten members will stop at six points between the departure point and the V&A Waterfront in Cape Town, where they will arrive on 16 September 2022.

Completing the estimated distance of 2 500 km

“The team that finishes with the greatest distance covered within the allotted time, will win the challenge,” says Dr Hendrik van Heerden from the UFS Department of Physics and project manager of Team UFS. 

The UFS, which has entered its solar-powered vehicle, Lengau (meaning Cheetah in Sesotho), will compete against more than 11 other teams, both local and international.

Dr Van Heerden’s two main objectives in entering the challenge, are to build a solar-powered vehicle robust enough to complete the estimated distance of 2 500 km during the 2022 Sasol Solar Challenge. Furthermore, he aims to establish capacity in the students and staff through acquired practical knowledge on the management, design, construction, and actual racing of solar-powered vehicles, which is to form the basis for participation in future projects and event competitions. 

Bringing together expertise from the UFS Departments of Physics, Engineering Sciences, Computer Sciences and Informatics, Electronics and Instrumentation, and Geography, the team of 23 started with the construction of their vehicle on 18 October 2021. 

Just over 10 months later and the car is fully functional, already passed a few road tests, and the crew is ready for the big challenge ahead.

The three drivers, Albert Dreyer, Monica van der Walt, Denver de Koker, together with back-up driver Lukas Erasmus, will travel on public roads via a predefined route over eight days, driving every day between 07:30 and 17:00. The aluminium-frame vehicle will weigh up to 370 kg, including the frame, the five solar panels, and the driver, and can reach a maximum speed of 60 km per hour (they aim to average 45 km/hour). 

According to the Sasol Solar Challenge rules and regulations, no driver is allowed to drive for longer than two hours. The capacity of the batteries and the availability of sun will determine how often the drivers will need to stop to recharge the solar batteries. 

Popularising electric vehicle technologies

This is the first time that Team UFS will be participating in the Sasol Solar Challenge. A guardedly optimistic Dr Van Heerden says their goal is to complete the full distance without breakages, and to accumulate as much knowledge and information as possible. With the next Sasol Solar Challenge in two years’ time, they plan to enter again. 

“Our long-term aim is to continually improve on the design, technology, science, and project implementation to participate in events and challenges around ‘green’ energy and relevant technologies. An additional aim is the popularisation of electric vehicle (EV) technologies through outreach programmes,” says Dr Van Heerden. 

Prof Koos Terblans, Head of the Department of Physics, says one of the key benefits of this project was that the group, consisting of personnel and students from different departments, learned to work together as one team. “Together, they worked and made plans to collect and apply the maximum amount of energy. Looking at the bigger picture, they are solving a worldwide problem, that of harvesting and applying energy. I am very excited that they have come this far; this is a first for the university.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept